3 Investigational new agents in LGL

3.1 Novel and Investigational Therapies

Code

# Novel therapeutic approaches
novel_tx <- tibble(
  Agent = c(
    "BNZ-1 (IL-15 inhibitor)",
    "DR-01 (anti-CD94)",
    "ABC008 (anti-KLRG1)",
    "KT-333 (STAT3 degrader)",
    "Siltuximab (anti-IL-6)",
    "Oral Azacitidine"
  ),
  Mechanism = c(
    "Blocks IL-15/γc cytokine binding",
    "Targets CD94 lectin receptor",
    "Targets coinhibitory TCR receptor",
    "STAT3 protein degradation",
    "IL-6 receptor blockade",
    "DNA hypomethylation"
  ),
  `Development Stage` = c(
    "Phase 1/2 completed",
    "Phase 1/2 recruiting",
    "Phase 1/2 recruiting",
    "Phase 1a/1b ongoing",
    "Phase 1 recruiting",
    "Phase 1 recruiting"
  ),
  `Preliminary Results` = c(
    "20% objective response",
    "Not yet available",
    "Not yet available",
    "Not yet available",
    "Not yet available",
    "Promising case report"
  ),
  `ClinicalTrials.gov ID` = c(
    "Not listed",
    "NCT05475925",
    "NCT05532722",
    "NCT05225584",
    "NCT05316116",
    "NCT05141682"
  )
)

novel_tx %>%
  kable(
    caption = "Novel and Investigational Therapies for LGL Leukemia",
    booktabs = TRUE
  ) %>%
  kable_styling(
    bootstrap_options = c("striped", "hover"),
    full_width = FALSE,
    font_size = 10
  ) %>%
  column_spec(2, width = "12em")

Novel and Investigational Therapies for LGL Leukemia
Agent	Mechanism	Development Stage	Preliminary Results	ClinicalTrials.gov ID
BNZ-1 (IL-15 inhibitor)	Blocks IL-15/γc cytokine binding	Phase 1/2 completed	20% objective response	Not listed
DR-01 (anti-CD94)	Targets CD94 lectin receptor	Phase 1/2 recruiting	Not yet available	NCT05475925
ABC008 (anti-KLRG1)	Targets coinhibitory TCR receptor	Phase 1/2 recruiting	Not yet available	NCT05532722
KT-333 (STAT3 degrader)	STAT3 protein degradation	Phase 1a/1b ongoing	Not yet available	NCT05225584
Siltuximab (anti-IL-6)	IL-6 receptor blockade	Phase 1 recruiting	Not yet available	NCT05316116
Oral Azacitidine	DNA hypomethylation	Phase 1 recruiting	Promising case report	NCT05141682

3.2 Ulviprubart (ABC008)

CD8+ CD57+ T cells can also express killer cell lectin-like receptor subfamily G member 1 (KLRG1), and depletion of KLRG1+ cells may be useful for the treatment of T-LGLL
Ulviprubart is an afucosylated monoclonal antibody specific for KLRG1
subcutaneous injections of ulviprubart Q4 weeks